Adaltis Inc., an international in vitro diagnostic company, announced that it has agreed to acquire control of Shanghai Hua Tai Biotechnology Co. Ltd. ("Hua Tai"), a manufacturer of infectious disease diagnostic products located in Shanghai, China. Hua Tai is a subsidiary of the FOSUN Group, a leading healthcare group in China.

This acquisition will strengthen Adaltis' existing presence in China by broadening its product offering and market penetration. Terms of the agreement were not disclosed. The closing of this transaction is expected in the first quarter of 2007, pending governmental approvals and satisfaction of customary conditions.

Hua Tai is a diagnostic company manufacturing and selling a suite of diagnostic tests for infectious diseases, mainly hepatitis reagents. Active in the Chinese in vitro diagnostic market for over 12 years, Hua Tai sells to laboratories and hospitals and employs 60 employees in production and sales. Adaltis plans to consolidate production in its new state-of-the art facility and integrate Hua Tai's sales organization into its existing operation.

"Adaltis remains committed to expanding its presence as a leader of in vitro diagnostic products in China. This acquisition will strengthen our core businesses in China, expand and deepen our customer relationships, bring us experienced new employees in production and sales, and increase our revenues. We look forward to the opportunity of bringing the Hua Tai assets, including products, capabilities and resources, into our company which will allow us to accelerate our growth strategy and build long-term shareholder value," said Mr. Pierre Larochelle, President and Chief Executive Officer of Adaltis Inc.

Source:未知